

The Prognostic Value of Normal Exercise Myocardial Perfusion Imaging and Exercise Echocardiography

A Meta-Analysis

Louise D. Metz, MD,* Mary Beattie, MD,† Robert Hom, MD,‡ Rita F. Redberg, MD, MSc,§ Deborah Grady, MD, MPH,||¶† Kirsten E. Fleischmann, MD, MPH§

New York, New York; and San Francisco, California

- Objectives** The purpose of this work was to determine the prognostic value of normal exercise myocardial perfusion imaging (MPI) tests and exercise echocardiography tests, and to determine the prognostic value of these imaging modalities in women and men.
- Background** Exercise MPI and exercise echocardiography provide prognostic information that is useful in the risk stratification of patients with suspected coronary artery disease (CAD).
- Methods** We searched the PubMed, Cochrane, and DARE databases between January 1990 and May 2005, and reviewed bibliographies of articles obtained. We included prospective cohort studies of subjects who underwent exercise MPI or exercise echocardiography for known or suspected CAD, and provided data on primary outcomes of myocardial infarction (MI) and cardiac death with at least 3 months of follow-up. Secondary outcomes (unstable angina, revascularization procedures) were abstracted if provided. Studies performed exclusively in patients with CAD were excluded.
- Results** The negative predictive value (NPV) for MI and cardiac death was 98.8% (95% confidence interval [CI] 98.5 to 99.0) over 36 months of follow-up for MPI, and 98.4% (95% CI 97.9 to 98.9) over 33 months for echocardiography. The corresponding annualized event rates were 0.45% per year for MPI and 0.54% per year for echocardiography. In subgroup analyses, annualized event rates were <1% for each MPI isotope, and were similar for women and men. For secondary events, MPI and echocardiography had annualized event rates of 1.25% and 0.95%, respectively.
- Conclusions** Both exercise MPI and exercise echocardiography have high NPVs for primary and secondary cardiac events. The prognostic utility of both modalities is similar for both men and women. (J Am Coll Cardiol 2007;49:227-37)
© 2007 by the American College of Cardiology Foundation

In addition to providing information regarding the diagnosis of coronary artery disease (CAD), noninvasive tests also provide prognostic information useful in risk stratification and clinical management. Accurate risk stratification has

become increasingly important to optimize patient outcomes and contain rapidly escalating medical care costs. Tests with high negative predictive values (NPVs) (low event rates after a negative test) are particularly useful because they identify low-risk persons who generally do not need additional tests and interventions. Both stress myocardial perfusion imaging (MPI) and stress echocardiography have prognostic value in patients suspected of having CAD, independent of the information provided by clinical factors and the exercise electrocardiogram (1-12).

See page 238

Moreover, exercise imaging tests for the diagnosis of CAD may have variable diagnostic accuracy in women compared with men. The accuracy of both exercise MPI and exercise echocardiography has been reported to be lower in women than in men (13).

From the *Department of Medicine, New York University School of Medicine, New York, New York; †Department of Medicine, University of California, San Francisco, California; ‡University of California, San Francisco School of Medicine, San Francisco, California; §Division of Cardiology, Department of Medicine, University of California, San Francisco, California; ||Department of Epidemiology and Biostatistics, University of California, San Francisco, California; and the ¶Medicine Section, Veterans Affairs Medical Center, San Francisco, California. This work was performed, in part, by the University of California, San Francisco-Stanford Evidence-Based Practice Center under contract to the Agency for Healthcare Research and Quality (contract no. 290-97-0013), the Women's Health Clinical Research Center at the University of California, San Francisco, and was supported in part by the U.S. Department of Veterans Affairs. Dr. Fleischmann was supported by an Outcomes Research Award from the American Society of Echocardiography.

Manuscript received February 16, 2006; revised manuscript received August 23, 2006, accepted August 28, 2006.

**Abbreviations
and Acronyms**

CAD = coronary artery disease
MPI = myocardial perfusion imaging
NPV = negative predictive value
SPECT = single-photon emission computed tomography

We performed a systematic review and meta-analysis to determine the NPV of exercise MPI, including thallium, sestamibi, and tetrofosmin, and exercise echocardiography. Our secondary aim was to assess the NPVs of these imaging modalities in women and men.

Methods

Study selection. A literature search was performed using the PubMed, Cochrane, and DARE databases to identify articles published between January 1990 and May 2005 as part of a larger review of the diagnostic accuracy of exercise MPI and echocardiography in women. The following search terms were used: *thallium radioisotopes, radiopharmaceuticals, tomography emission-computed single-photon, technetium Tc 99m sestamibi, organotechnetium compounds, SPECT, Cardiolite, Mibi, tetrofosmin, technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane, echocardiography, ultrasound, ultrasonography, exercise, exercise test, exercise tolerance, exercise*, exercising, "stress test"; and diagnosis, diagnoses, diagnostic, diagnosing, predictive values of test.* The search was not restricted to English-language literature. Bibliographies of all articles obtained were reviewed to identify additional articles. The date limits were chosen because both exercise echocardiography and exercise MPI using single-photon emission computed tomography (SPECT) with thallium and sestamibi were in widespread use during this period.

Studies were included if they met the following criteria: 1) prospective cohort studies of subjects who underwent exercise SPECT MPI or exercise echocardiography for known or suspected CAD; 2) provided primary data on clinical outcomes of myocardial infarction or cardiac death; 3) follow-up time of 3 months or more; and 4) defined a normal stress MPI or echocardiography test as one without any fixed or reversible perfusion deficit (for MPI) or fixed or inducible wall motion abnormalities (for echocardiography). Studies were excluded if they met the following criteria: 1) noninvasive tests were performed exclusively in patients after myocardial infarction, percutaneous angioplasty, coronary bypass surgery, hospitalization for unstable coronary syndrome, or with documented CAD by angiography; 2) included pharmacologic imaging tests without presenting data separately for pharmacologic and exercise testing; 3) did not include primary outcome data or event rates that could be statistically combined in a meta-analysis; or 4) evaluated planar MPI instead of SPECT. When multiple studies from the same research group were identified, only the largest study was included to avoid potential duplication in patient cohorts.

An initial search identified 3,563 potentially eligible articles. Two investigators reviewed the titles and excluded those that clearly did not provide data on humans or did not

address the research question. The abstracts of the remaining articles were reviewed independently by 2 physician investigators to determine eligibility. Disagreements were resolved by consensus.

Data abstraction. Two investigators (L.M. and R.H.), blinded to the journal, author, year of publication, and institution, independently reviewed the full text of each potentially eligible study and abstracted data including characteristics of the study, participant characteristics, test characteristics, mean follow-up time, and percentage of the population lost to follow-up. Occurrence of primary outcomes (nonfatal myocardial infarction or cardiac death) and secondary outcomes (revascularization and admission for unstable angina) were recorded. Results, including number of events or event rates based on positive or negative tests, relative risks or hazard ratios for future events, incremental prognostic value based on Cox proportional hazards model, and variables used in multivariate analysis, were abstracted. Results stratified by gender were abstracted separately when provided.

Quality assessment. A quality assessment was performed by the 2 blinded investigators based on presence of the following parameters: 1) complete follow-up for 90% or more of the baseline cohort; 2) outcome data were obtained by investigators blinded to the test results; and 3) whether hospital records and death certificates were used to corroborate outcomes. Studies were defined as good quality if they fulfilled the criterion of 90% or greater follow-up and at least 1 of the other 2 criteria. Fair-quality studies fulfilled only 1 of the criteria and poor-quality studies fulfilled none of the criteria.

Statistical analysis. The primary analysis determined the summary estimate of the rate of myocardial infarction or cardiac death after a normal noninvasive test. Secondary analysis determined summary estimates of the rate of revascularization or unstable angina after a normal test. Pooled summary estimates and 95% confidence intervals for event rates after a negative noninvasive test were calculated from the primary data with each study result weighted by sample size using STATA software (version 8.0, STATA Corp., College Station, Texas). These analyses were repeated in subgroups of studies of MPI based on the criteria for defining a positive test, the radioisotope used, gender, and follow-up time. Findings were assessed for heterogeneity using a Q statistic, with a p value <0.10 considered statistically significant.

Estimated annual event rates were calculated with the caveat that the occurrence of events may not be linear. Estimated annualized event rates for each study were calculated as averages over the lengths of follow-up, and pooled summary annualized event rates were calculated by weighting study estimates by sample size.

A multivariate analysis was performed using STATA software. We used weighted multiple linear regression models to assess the dependence of the event rate after a normal test on characteristics of each study, including

average age of participants, percent of participants with prior myocardial infarction, percent women, and length of follow-up. Analyses were weighted in proportion to the number of subjects in each study.

A sensitivity analysis based on study quality was performed by stratifying the studies into 2 groups, good quality and fair or poor quality, and calculating the summary estimates in each group. Publication bias was assessed by calculating the correlation coefficient, Kendall's tau, for the association of sample size and event rate after a negative test (14).

Results

Study identification. The initial literature search yielded 3,563 study titles. Among these, 148 full-text articles evaluating the prognostic utility of exercise MPI or exercise echocardiography were reviewed, and 20 studies were found to be eligible for the systematic review. Of the 148 full-text articles reviewed, 17 did not address the research question (15-31), 18 were excluded because they used pharmacologic rather than exercise stress (32-49), 27 did not include primary data on event rates that could be combined in a meta-analysis (47,50-75), 16 did not address a population with known or suspected CAD (76-91), 5 evaluated only hospitalized patients or patients evaluated for chest pain syndromes in the emergency department (92-96), 16 included only patients with angiographically proven CAD or positive tests (97-112), 21 were potentially overlapping patient populations of other studies (53,113-132), 5 evaluated planar MPI (133-137), and 3 did not define a negative test as one without any abnormalities (138-140).

Of the 17 studies included that evaluated MPI (141-156), 5 used thallium (143,147,153,154,157), 8 used sesta-

mibi (141,142,146,148-150,152,156), 2 used both thallium and sestamibi (145,155), and 2 used tetrofosmin (144,151). Ten of the 17 MPI studies measured rates of unstable angina and revascularization in addition to primary events (141-145,147,148,152,154,156), and 3 stratified the data by gender (53,120,128). Of the 4 studies of exercise echocardiography (115,154,158,159), 2 included data on rates of unstable angina and revascularization in addition to myocardial infarction and cardiac death (154,158) and 2 stratified data by gender (140,158).

Predictive value of exercise MPI. The 17 exercise MPI studies included 8,008 subjects with a mean age of 54 years, of whom 34% were women (Table 1). A normal MPI test was defined as the absence of any fixed or reversible defect in each of the studies. The risk of myocardial infarction or cardiac death after a normal test was 1.2% with a NPV of 98.8% over a mean follow-up of 36 months, corresponding to an estimated annualized event rate of 0.45% per year if a presumption of linear event rates is made (Table 1). The test of heterogeneity demonstrated that the MPI study results are homogeneous ($Q = 13.06$, $p = 0.7321$).

Ten studies evaluated the predictive value of exercise MPI for cardiac revascularization or unstable angina; risk for these events after a normal test was 3.4% with an NPV of 96.6% over a mean follow-up of 36 months, corresponding to an annualized event rate of 1.25% per year (Tables 2 and 3).

Predictive value of thallium versus sestamibi versus tetrofosmin MPI. The NPV for the risk of myocardial infarction or cardiac death was approximately 97% over a mean follow-up of 45 months for thallium, approximately 99% after a normal sestamibi test over a mean follow-up of

Table 1 Studies of the Value of Exercise Myocardial Perfusion Imaging to Predict MI and Cardiac Death

| Reference | Radionuclide Used | n | Mean Age (yrs) | Women (%) | Prior MI (%) | Mean Follow-Up (Months) | Event Rate After Negative Test (%) (95% CI) | Negative Predictive Value (%) (95% CI) | Annualized Event Rate (%) |
|----------------------------|-------------------|-------|----------------|-----------|--------------|-------------------------|---|--|---------------------------|
| Ambrosi et al. (157) | TI | 84 | 59 | 28 | * | 46 | 3.6 | 96.4 | 0.93 |
| Boyne et al. (141) | MIBI | 155 | 58 | 50 | 27 | 19 | 1.3 | 98.7 | 0.81 |
| Chatzioannou et al. (142) | MIBI | 230 | 54 | 13 | 20 | 18 | 0 | 100 | 0 |
| del Val Gomez et al. (143) | TI | 85 | 56 | 53 | * | 24 | 0 | 100 | 0 |
| Elhendy et al. (156) | MIBI | 218 | 53 | 50 | 6 | 89 | 5.0 | 95.0 | 0.68 |
| Galassi et al. (144) | Tetro | 106 | 58 | 22 | 55 | 38 | 2.8 | 97.2 | 0.89 |
| Hachamovitch et al. (155) | TI/MIBI | 4,791 | 61 | 49 | 0 | 22 | 0.4 | 99.6 | 0.2 |
| Kaminek et al. (145) | TI or MIBI | 147 | * | 28 | * | 24 | 0.7 | 99.3 | 0.34 |
| Olmos et al. (154) | TI | 115 | 56 | 24 | 35 | 44 | 3.5 | 96.5 | 0.95 |
| Pattillo et al. (153) | TI | 196 | 59 | 29 | 47 | 41 | 3.6 | 96.4 | 1.0 |
| Raiker et al. (152) | MIBI | 208 | 59 | 48 | 4.8 | 14 | 0.5 | 99.5 | 0.41 |
| Schinkel et al. (151) | Tetro | 294 | 56 | 33 | 27 | 48 | 1.0 | 99.0 | <0.3 |
| Soman et al. (150) | MIBI | 426 | 56 | 42 | 6 | 30 | 0 | 100 | 0 |
| Stratmann et al. (149) | MIBI | 206 | * | 2 | 35 | 13 | 0.5 | 99.5 | 0.45 |
| Sugihara et al. (148) | MIBI | 104 | 68 | 42 | 18 | 13 | 0 | 100 | 0 |
| Vanzetto et al. (147) | TI | 388 | 55 | 25 | 24 | 72 | 3.4 | 96.6 | 0.56 |
| Zerahn et al. (146) | MIBI | 255 | 57 | 36 | 51 | 59 | 3.1 | 96.9 | 0.64 |
| Summary estimate | | 8,008 | 54.1 | 33.8 | | 36.1 | 1.21 (0.98-1.48) | 98.8 (98.5-99.0) | 0.45 |

*Patient characteristics not provided.

CI = confidence interval; MI = myocardial infarction; MIBI = sestamibi; Tetro = tetrofosmin; TI = thallium; TI/MIBI = both thallium and sestamibi.

Table 2 Studies of the Value of Exercise Myocardial Perfusion Imaging to Predict Revascularization and Unstable Angina

| Reference | Radionuclide Used | n | Mean Age (yrs) | Women (%) | Prior MI (%) | Mean Follow-Up (Months) | Event Rate After Negative Test (%) (95% CI) | Negative Predictive Value (%) (95% CI) | Annualized Event Rate (%) |
|----------------------------|-------------------|-------|----------------|-----------|--------------|-------------------------|---|--|---------------------------|
| Boyne et al. (141) | MIBI | 155 | 58 | 50 | 27 | 19 | 1.3 | 98.7 | 0.81 |
| Chatziloannou et al. (142) | MIBI | 230 | 54 | 13 | 20 | 18 | 1.7 | 98.3 | 1.16 |
| del Val Gomez et al. (143) | Tl | 85 | 56 | 53 | * | 24 | 1.2 | 98.8 | 0.59 |
| Elhendy et al. (156) | MIBI | 218 | 53 | 50 | 6 | 89 | 6.9 | 93.1 | 0.93 |
| Galassi et al. (144) | Tetro | 106 | 58 | 22 | 55 | 38 | 5.7 | 94.3 | 1.79 |
| Kaminek et al. (145) | Tl/MIBI | 147 | * | 28 | * | 24 | 4.1 | 95.9 | 2.04 |
| Olmos et al. (154) | Tl | 115 | 56 | 24 | 35 | 44 | 3.5 | 96.5 | 0.95 |
| Raiker et al. (152) | MIBI | 208 | 59 | 48 | 4.8 | 14 | 1.9 | 98.1 | 1.65 |
| Sugihara et al. (148) | MIBI | 104 | 68 | 42 | 18 | 13 | 3.8 | 96.2 | 3.55 |
| Vanzetto et al. (147) | Tl | 388 | 55 | 25 | 24 | 72 | 0.6/yr | 99.4 | 0.60 |
| Summary estimate | | 1,756 | 51.7 | 35.5 | | 35.5 | 3.42 (2.61-4.40) | 96.6 (95.6-97.4) | 1.25 |

*Patient characteristics not provided.
Abbreviations as in Table 1.

32 months, over 99% when both isotopes were used over a mean follow-up of 23 months, and 99% after a normal tetrofosmin test over a mean follow-up of 43 months. The corresponding annualized event rates were approximately 0.7% for thallium, 0.3% for sestamibi, 0.5% when both isotopes were used, and 0.4% for tetrofosmin (Table 3).

Predictive value of exercise MPI in women compared with men. Two studies focused on exercise MPI studies in women as part of larger databases included in the aforementioned summary estimates (120,128), and 1 study stratified by gender (53). The NPVs of myocardial infarction or cardiac death after a normal test were approximately 99% over an average follow-up of 32 months in women and 99% over 20 months in men. The annualized event rates were approximately 0.3% for women and 0.8% for men (Table 4).

Predictive value of exercise MPI among subgroups based on duration of follow-up. The mean duration of follow-up was between 1 and 3 years in 9 studies (141-143,145,148-150,152,155), including 6,352 subjects; between 3 and 5 years in 6 studies (144,146,151,153,154,157), including 1,050 subjects; and 6 to 8 years in 2 studies (147,156), including 606 subjects. The rate of myocardial

infarction and cardiac death was 0.7% over a mean follow-up of 20 months in the 1- to 3-year subgroup, corresponding to an annualized event rate of 0.4%. The event rate was 2.7% over a mean follow-up of 46 months in the 3- to 5-year subgroup, corresponding to an annualized event rate of 0.7%. The 6- to 8-year follow-up subgroup had an event rate of 4% over a mean follow-up of 81 months, or a 0.6% annualized event rate.

Exercise echocardiography. The 4 eligible studies of the predictive value of exercise echocardiography included 3,021 subjects with a mean age of 56 and 46% women (Table 5). A normal test was defined as the absence of any wall motion abnormalities with stress or rest in all studies. The rate of myocardial infarction or cardiac death after a normal test was approximately 1.6% with an NPV of 98% over the mean follow-up of 33 months, corresponding to an estimated annualized event rate of 0.54% (Tables 3 and 5). The test of heterogeneity demonstrated that the exercise echocardiography study results are homogeneous ($Q = 0.46, p = 0.7952$).

Two of the studies, including 380 subjects, included data on rates of unstable angina and revascularization. The NPV for these events was approximately 97% over a mean

Table 3 Summary Estimates of Event Rates After a Negative Test and Negative Predictive Values for MI and Cardiac Death, and Revascularization and Unstable Angina After a Negative Test

| Exercise Imaging Modality and Events | n | Mean Follow-Up (Months) | Mean Age (yrs) | Women (%) | Summary Event Rate After a Negative Test (%) (95% CI) | Negative Predictive Value (%) (95% CI) | Annualized Event Rate (%) |
|--|-------|-------------------------|----------------|-----------|---|--|---------------------------|
| MI and cardiac death | | | | | | | |
| MPI | 8,008 | 36 | 54 | 34 | 1.21 (0.98-1.48) | 98.8 (98.5-99.0) | 0.45 |
| Thallium | 868 | 45 | 57 | 32 | 3.11 (2.05-4.53) | 96.9 (95.5-97.9) | 0.70 |
| Sestamibi | 1,802 | 32 | 58 | 35 | 1.28 (0.81-1.92) | 98.7 (98.1-99.2) | 0.34 |
| Thallium/sestamibi | 4,938 | 23 | 61 | 39 | 0.83 (0.60-1.13) | 99.2 (98.9-99.4) | 0.45 |
| Tetrofosmin | 400 | 43 | 57 | 28 | 1.5 (0.55-3.26) | 98.5 (96.8-99.4) | 0.42 |
| Echo | 3,021 | 33 | 56 | 46 | 1.56 (1.14-2.07) | 98.4 (97.9-98.9) | 0.54 |
| Revascularization and unstable angina | | | | | | | |
| MPI | 1,756 | 36 | 52 | 36 | 3.42 (2.61-4.40) | 96.6 (95.6-97.4) | 1.25 |
| Echo | 380 | 32 | 54 | 45 | 2.63 (1.26-4.84) | 97.4 (95.2-98.7) | 0.95 |

Echo = echocardiography; MPI = myocardial perfusion imaging; other abbreviations as in Table 1.

Table 4 Summary Estimates of Rates After a Negative Test and Negative Predictive Value for Myocardial Infarction or Cardiac Death for Women and Men in Exercise Myocardial Perfusion Imaging and Exercise Echo

| Exercise Imaging Modality | n | Mean Follow-Up (Months) | Summary Event Rate After Negative Test (%) (95% CI) | Negative Predictive Value (%) (95% CI) | Annualized Event Rate (%) |
|---------------------------|-------|-------------------------|---|--|---------------------------|
| MPI | | | | | |
| All | 2,900 | 32 | 1.03 (0.70-1.48) | 99.0 (98.5-99.3) | 0.58 |
| Women | 1,443 | 32 | 0.69 (0.33-1.27) | 99.3 (98.7-99.7) | 0.33 |
| Men | 1,457 | 20 | 1.37 (0.84-2.12) | 98.6 (97.9-99.2) | 0.82 |
| Echo | | | | | |
| All | 5,946 | 37.6 | 3.23 (2.70-3.82) | 96.8 (96.2-97.3) | 1.03 |
| Women | 2,547 | 37.6 | 2.34 (1.71-3.13) | 97.7 (96.9-98.3) | 0.75 |
| Men | 3,399 | 37.6 | 3.90 (3.12-4.81) | 96.1 (95.2-96.9) | 1.24 |

Abbreviations as in Tables 1 and 3.

follow-up of 32 months, corresponding to an annualized event rate of 0.95% (Tables 3 and 6).

Predictive value of exercise echocardiography in women and men. Only 2 of the exercise echocardiography studies provided primary data stratified by gender, both of which found high NPVs for both men and women (140,158). The NPV was 98% in women over 38 months of follow-up, and 96% in men over 38 months of follow-up, corresponding to annualized event rates of 0.75% in women and 1.24% in men (Table 4).

Predictive value of exercise echocardiography among subgroups based on duration of follow-up. The mean duration of follow-up was between 1 and 3 years in 2 studies (158,159), including 263 subjects, and between 3 and 4 years in 2 studies (115,154), including 2,758 subjects. The rate of myocardial infarction and cardiac death was approximately 2% over a mean follow-up of 26 months in the 1- to 3-year subgroup, corresponding to an annualized event rate of 0.9%. The event rate was 1.5% over a mean follow-up of 40 months in the 3- to 4-year subgroup, corresponding to an annualized event rate of 0.5%.

Multivariate analysis. Separate multivariate analyses were performed to determine the effect of cohort characteristics on the NPV of the MPI and echocardiography. For MPI, the rate of myocardial infarction and cardiac death after a normal test was about 0.2 percentage points higher for each 10 percentage point increase in proportion of subjects with a prior myocardial infarction. There was no significant difference in event rate after MPI related to percentage of

women or mean age of the cohort. For stress echocardiography, the percentage of women in the study was the only variable that was significantly associated with the rates of myocardial infarction and cardiac death after a negative test. For each 10 percentage point increase in the proportion of women in the study, the event rate after a normal test was approximately 1 percentage point lower.

Effect of the quality of the studies on the predictive value of noninvasive tests. Nine studies were considered good quality (141,142,149-152,154-156) and 10 fair or poor quality (143-148,153,157-159). For both exercise MPI and echocardiography, event rates after a normal test were similar when fair- and poor-quality studies were excluded.

Publication bias. There was no evidence of significant publication bias for either MPI (Kendall's tau = -0.29, p = 0.06) or exercise echocardiography studies (Kendall's tau = -0.33, p = 0.25).

Discussion

Our systematic review and meta-analysis evaluating the prognostic utility of exercise MPI and exercise echocardiography demonstrated that the NPVs of both exercise imaging modalities are high. Although formal statistical comparison of the tests cannot be performed due to differing length of follow-up, possible nonlinearity of events, and inability to adjust fully for differences in factors that may affect the risk of cardiac events, the event rates with a normal test were low for both exercise MPI and echocardi-

Table 5 Studies of the Value of Exercise Echocardiography to Predict MI and Cardiac Death

| Reference | n | Mean Age (yrs) | Women (%) | Prior MI (%) | Mean Follow-Up (Months) | Event Rate After Negative Test (%) (95% CI) | Negative Predictive Value (%) (95% CI) | Annualized Event Rate (%) |
|----------------------|-------|----------------|-----------|--------------|-------------------------|---|--|---------------------------|
| Elhendy et al. (115) | 2,641 | 61 | 49 | 6 | 36 | 1.4 | 98.6 | 0.48 |
| Ismail et al. (159) | 115 | 53 | 63 | * | 23 | 2.6 | 97.4 | 1.36 |
| Olmos et al. (154) | 117 | 56 | 24 | 35 | 44 | 3.4 | 96.6 | 0.93 |
| Sawada et al. (158) | 148 | 53 | 48 | * | 28 | 1.4 | 98.6 | 0.19 |
| Summary estimate | 3,021 | 55.8 | 46 | | 32.8 | 1.56 (1.14-2.07) | 98.4 (97.9-98.9) | 0.54 |

*Patient characteristics not provided.
CI = confidence interval; MI = myocardial infarction.

Table 6 Studies of the Value of Exercise Echocardiography to Predict Revascularization and Unstable Angina

| Reference | n | Mean Age (yrs) | Women (%) | Prior MI (%) | Mean Follow-Up (Months) | Event Rate After Negative Test (%) (95% CI) | Negative Predictive Value (%) (95% CI) | Annualized Event Rate (%) |
|---------------------|-----|----------------|-----------|--------------|-------------------------|---|--|---------------------------|
| Olmos et al. (154) | 117 | 56 | 24 | 35 | 44 | 4.3 | 95.7 | 1.17 |
| Ismail et al. (159) | 115 | 53 | 63 | * | 23 | 0.9 | 99.1 | 0.45 |
| Sawada et al. (158) | 148 | 53 | 48 | * | 28 | 2.7 | 97.3 | 1.16 |
| Summary estimate | 380 | 54 | 45 | | 31.7 | 2.63 (1.26-4.84) | 97.4 (95.2-98.7) | 0.95 |

*Patient characteristics not provided.

CI = confidence interval; MI = myocardial infarction.

ography based on estimated annualized event rates. The estimated annualized rate of myocardial infarction or cardiac death was 0.45% per year after a negative MPI test, and 0.54% per year after a normal echocardiography test. These annualized event rates are both similar to a normal age-matched population, who carry a rate of <1% per year (160). Thus, both noninvasive imaging modalities accurately identify low-risk patients.

The development of myocardial ischemia begins with coronary stenoses, which lead initially to hypoperfusion, followed by wall motion abnormalities, a temporal sequence known as the ischemic cascade. The later development of wall motion abnormalities in this sequence suggests that stress MPI may be more sensitive in detecting CAD, and therefore more useful for prognosis than stress echocardiography. However, in our analysis, we found that normal echocardiography and MPI are both associated with low event rates similar to the general population.

The estimated annualized event rates for thallium, sestamibi, combined thallium/sestamibi, and tetrofosmin were all <1%. Therefore, each of the nuclear isotopes or combination of isotopes has a high NPV and is useful in identification of low-risk patients.

Some studies evaluating the diagnostic accuracy of stress electrocardiography, MPI, and echocardiography have found differing tests characteristics in women compared with men, and there is debate as to whether any particular modality may be more accurate in women (13,161). In our systematic review, both men and women with normal MPI tests had annualized event rates of <1%. Among the 2 exercise echocardiography studies that provided data stratified by gender, the annualized event rate after a normal test was <1% in women, and about 1% in men. It is important to note that we did not have high power to detect a difference in event rates between gender subgroups. However, the available data suggest that both noninvasive tests are useful to identify low-risk patients in both men and women.

Subgroup analyses based on follow-up time showed a slight increase in absolute event rate with increasing follow-up time for MPI, with an estimated annualized event rate <1% for each of the subgroups. Among the echocardiographic studies, longer duration of follow-up was not associated with increased event rates. However, the longest follow-up averaged only 3 to 4 years, and the subgroup with

1 to 3 years of follow-up included only 263 subjects compared with 2,758 in the group with longer follow-up, limiting the power to detect a true difference between the groups.

Although events such as myocardial infarction and cardiac death are almost universally evaluated in studies of prognosis and are considered least susceptible to bias, admissions for unstable angina or heart failure, revascularization, and anginal symptoms are associated with high costs and resource utilization, as well as substantial patient risk. In addition, as technology and medical treatments improve, rates of myocardial infarction and cardiac death are decreasing, and other outcomes, such as angina and revascularization, are becoming more common (162). In our study, the NPVs for revascularization and admissions for unstable angina were high for both exercise MPI and echocardiography. Estimated annualized event rates for secondary events were approximately 1% per year for both MPI and echocardiography.

Stress imaging tests can be used for risk stratification (1). Bayesian analysis indicates that stress tests are most useful for patients with intermediate pre-test probability of disease by moving them into a higher- or lower-risk group, thereby informing the choice of additional diagnostic tests, interventions, and medical management, which are costly and carry significant risks. By identifying a low-risk group of patients, defined by an annual event rate of <1%, additional interventions can be avoided in most cases (160). Our study indicates that both exercise MPI and exercise echocardiography are useful in identifying such low-risk patients over a spectrum of pre-test probabilities. Even in study cohorts or subsets of patients with relatively high pre-test probability, such as those with a higher percentage of prior myocardial infarction or positive exercise treadmill tests, the primary event rate with normal exercise MPI or echocardiography is relatively low (129,136,144,153). In multivariate analyses, markers of pre-test probability had modest effects on the event rates with a normal test, although there was a trend toward increased event rates in studies having higher percentages of prior myocardial infarction for MPI, but not for echocardiography.

The main limitation of our meta-analysis is that our summary estimates of event rates are unadjusted for some factors that may affect risk of cardiac events. Few of the studies included in the analysis provided adjusted relative risks of events. Multivariate models were used in many of the

studies, but these models commonly assessed incremental value, which do not provide statistics that can be combined across studies.

Several studies of large cohorts undergoing exercise MPI or echocardiography were not included in this review due to lack of primary data that could be combined in meta-analysis or inclusion of pharmacologic tests. These studies had findings consistent with our meta-analysis (22,38,40,54,57,60,61).

Assessments of the prognostic value of a test are susceptible to referral bias or the preferential referral to further testing or intervention in subjects with a positive test. In studies of prognosis, referral bias could result in a relatively higher event rate after a negative test. Despite potential referral bias, the NPVs of both imaging tests were high in our study.

We did not include analyses of positive predictive values in our systematic review. These values are particularly subject to bias due to differing patient risk factor profiles, and the effect of positive tests on subsequent revascularization and medical management. Although many studies included in our meta-analysis attempted to deal with referral bias by excluding subjects with early revascularization, this bias persists in unadjusted results.

Spectrum bias, or variation in test performance among persons at higher or lower risk of disease, may also affect the results of prognostic studies (163). Our systematic review includes studies of cohorts with varying pre-test risk of disease, as manifested by a broad range of percentage of subjects with prior myocardial infarction, advanced age, and male gender. Estimated annualized event rates were low, around 1% or less, for each of the studies despite varying pre-test risk of disease. Our multivariate analysis showed that event rates after a negative test increased minimally with increasing percentages of prior myocardial infarction for MPI, and did not increase for echocardiography. However, the studies included in our review did not include patient cohorts at higher risk of events, such as those who have recently had a myocardial infarction or undergone revascularization, and those undergoing pharmacologic imaging tests, and should, therefore, not be generalized to these populations. Although our study demonstrated the low annualized event rate generally associated with negative stress imaging tests, a negative test may not be associated with a low risk of events in certain populations, including diabetics (39,81,82).

In addition to the prognostic utility of perfusion defects and wall motion abnormalities, other exercise imaging parameters have also been shown to carry prognostic value, although they were outside the scope of this meta-analysis. In particular, Duke treadmill score (11,164,165), heart rate recovery (166,167), ischemic left ventricular dilation (168), and change in end-systolic volume (169) have been shown to have independent prognostic value.

Conclusions. Our systematic review demonstrates that both exercise MPI, including thallium, sestamibi, and com-

bination thallium/sestamibi, and exercise echocardiography have high NPVs for primary and secondary cardiac events. The event rates after normal tests with each modality are low, suggesting that the use of any of these noninvasive tests is appropriate, depending on experience and cost at particular institutions. In addition, the prognostic utility of both modalities is generally similar for both men and women. The NPVs of exercise MPI and echocardiography are useful in clinical practice to identify low-risk patients, thereby avoiding unnecessary tests and interventions.

Acknowledgments

The authors would like to thank statisticians Dan Moore and Eric Vittinghoff of the UCSF Women's Health Clinical Research Center for providing statistical analysis.

Reprint requests and correspondence: Dr. Kirsten Fleischmann, University of California, San Francisco, Box 0124, M M1177, San Francisco, California 94143. E-mail: fleischm@medicine.ucsf.edu.

REFERENCES

1. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. *N Engl J Med* 1979;300:1350-8.
2. Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging. A diagnostic tool comes of age. *Circulation* 1991;83:363-81.
3. Brown KA. Prognostic value of cardiac imaging in patients with known or suspected coronary artery disease: comparison of myocardial perfusion imaging, stress echocardiography, and position emission tomography. *Am J Cardiol* 1995;75:35-41D.
4. Brown KA, Rosman DR, Dave RM. Stress nuclear myocardial perfusion imaging versus stress echocardiography: prognostic comparisons. *Prog Cardiovasc Dis* 2000;43:231-44.
5. Geleijnse ML, Elhendy A. Can stress echocardiography compete with perfusion scintigraphy in the detection of coronary artery disease and cardiac risk assessment? *Eur J Echocardiogr* 2000;1:12-21.
6. Bonow RO. Diagnosis and risk stratification in coronary artery disease: nuclear cardiology versus stress echocardiography. *J Nucl Cardiol* 1997;4:S172-8.
7. Rozanski A, Gottdiener JS. Stress radionuclide imaging versus stress echocardiography: a framework for comparisons. *Prog Cardiovasc Dis* 2001;43:275-9.
8. Marwick TH. Use of stress echocardiography for the prognostic assessment of patients with stable chronic coronary artery disease. *Eur Heart J* 1997;18 Suppl D:D97-101.
9. Marwick TH. Stress echocardiography. *Heart* 2003;89:113-8.
10. Mark DB, Hlatky MA, Harrell FE Jr., Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. *Ann Intern Med* 1987;106:793-800.
11. Mark DB, Shaw L, Harrell FE Jr., et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. *N Engl J Med* 1991;325:849-53.
12. Morris CK, Ueshima K, Kawaguchi T, Hideg A, Froelicher VF. The prognostic value of exercise capacity: a review of the literature. *Am Heart J* 1991;122:1423-31.
13. Kwok Y, Kim C, Grady D, Segal M, Redberg R. Meta-analysis of exercise testing to detect coronary artery disease in women. *Am J Cardiol* 1999;83:660-6.
14. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088-101.
15. Hosie CJ, Rodger JC, Railton R. The value of thallium scintigraphy in a district general hospital. *Nucl Med Commun* 1993;14:12-4.
16. Lee DS, Jang MJ, Cheon GJ, Chung JK, Lee MC. Comparison of the cost-effectiveness of stress myocardial SPECT and stress echocardiography in suspected coronary artery disease considering

- the prognostic value of false-negative results. *J Nucl Cardiol* 2002; 9:515-22.
17. Daly C, Norrie J, Murdoch DL, Ford I, Dargie HJ, Fox K. The value of routine non-invasive tests to predict clinical outcome in stable angina. *Eur Heart J* 2002;24:532-40.
 18. Miller TD, Roger VL, Milavetz JJ, et al. Assessment of the exercise electrocardiogram in women versus men using tomographic myocardial perfusion imaging as the reference standard. *Am J Cardiol* 2001;87:868-73.
 19. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. *Circulation* 2003;107:2900-7.
 20. Garcia MJ, Neumann D, Go RT, et al. Comparison of persistent thallium perfusion defects by quantitative washout analysis with thallium reinjection in patients with coronary artery disease. *Am J Cardiol* 1994;74:977-81.
 21. Pollock SG, Abbott RD, Boucher CA, Beller GA, Kaul S. Independent and incremental prognostic value of tests performed in hierarchical order to evaluate patients with suspected coronary artery disease. Validation of models based on these tests. *Circulation* 1992;85:237-48.
 22. Gibson PB, Demus D, Noto R, Hudson W, Johnson LL. Low event rate for stress-only perfusion imaging in patients evaluated for chest pain. *J Am Coll Cardiol* 2002;39:999-1004.
 23. Nallamothu N, Panchoy SB, Lee KR, Heo J, Iskandrian AS. Impact on exercise single-photon emission computed tomographic thallium imaging on patient management and outcome. *J Nucl Cardiol* 1995;2:334-8.
 24. Sharir T, Germano G, Kavanagh PB, et al. Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography. *Circulation* 1999;100:1035-42.
 25. Obeidat O, Arida M, Al-Mallah M, Alam M, Ananthasubramaniam K. Segmental early relaxation phenomenon: incidence, clinical characteristics, and significance in stress echocardiography. *Chest* 2004; 125:1218-23.
 26. Hayes SW, De Lorenzo A, Hachamovitch R, et al. Prognostic implications of combined prone and supine acquisitions in patients with equivocal or abnormal supine myocardial perfusion SPECT. *J Nucl Med* 2003;44:1633-40.
 27. Poornima IG, Miller TD, Christian TF, Hodge DO, Bailey KR, Gibbons RJ. Utility of myocardial perfusion imaging in patients with low-risk treadmill scores. *J Am Coll Cardiol* 2004;43:194-9.
 28. Worthley MI, Unger SA, Mathew TH, Russ GR, Horowitz JD. Usefulness of tachycardic-stress perfusion imaging to predict coronary artery disease in high-risk patients with chronic renal failure. *Am J Cardiol* 2003;92:1318-20.
 29. Candell-Riera J, Oller-Martinez G, Perezto-Valdes O, et al. Usefulness of myocardial perfusion SPECT in patients with left bundle branch block and previous myocardial infarction. *Heart* 2003;89: 1039-42.
 30. Lapeyre AC 3rd, Poornima IG, Miller TD, Hodge DO, Christian TF, Gibbons RJ. Prognostic value of exercise stress myocardial perfusion imaging in patients with permanent pacemakers. *Am J Cardiol* 2004;94:811-4.
 31. Elhendy A, Schinkel AF, van Domburg RT, Bax JJ, Poldermans D. Incidence and predictors of heart failure during long-term follow-up after stress Tc-99m sestamibi tomography in patients with suspected coronary artery disease. *J Nucl Cardiol* 2004;11:527-33.
 32. Kamalesh M, Matorih R, Sawada S. Comparative prognostic significance of transeophageal versus transthoracic echocardiography. *Echocardiography* 2002;19:313-8.
 33. Font VE, Lara WC, Bournigal DR. Stress echocardiography for predicting cardiac events in octogenarians: is myocardial perfusion scintigraphy necessary anymore? *South Med J* 1996;89:1166-73.
 34. Groutars RG, Verzijlbergen JF, Muller AJ, et al. Prognostic value and quality of life in patients with normal rest thallium-201/stress technetium 99m-tetrofosmin dual-isotope myocardial SPECT. *J Nucl Cardiol* 2000;7:333-41.
 35. Dodi C, Cortigiani L, Masini M, Olivotto I, Azzarelli A, Nannini E. The incremental prognostic value of pharmacological stress echo over exercise electrocardiography in women with chest pain of unknown origin. *Eur Heart J* 2001;22:145-52.
 36. Machecourt J, Longere P, Fagret D, et al. Prognostic value of thallium-201 single-photon emission computed tomographic myocardial perfusion imaging according to extent of myocardial defect. Study in 1,926 patients with follow-up at 33 months. *J Am Coll Cardiol* 1994;23:1096-106.
 37. Giri S, Shaw LJ, Murthy DR, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. *Circulation* 2002;105:32-40.
 38. Marwick TH, Case C, Sawada S, Vasey C, Thomas JD. Prediction of outcomes in hypertensive patients with suspected coronary artery disease. *Hypertension* 2002;39:1113-8.
 39. Marwick TH, Case C, Sawada S, Vasey C, Short L, Lauer M. Use of stress echocardiography to predict mortality in patients with diabetes and known or suspected coronary artery disease. *Diabetes Care* 2002;25:1042-8.
 40. Shaw LJ, Miller DD, Romeis JC, Kargl D, Younis LT, Chaitman BR. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. *Ann Intern Med* 1994;120:559-66.
 41. Davar JI, Roberts EB, Coghlan JG, Evans TR, Lipkin DP. Prognostic value of stress echocardiography in women with high (> or = 80%) probability of coronary artery disease. *Postgrad Med J* 2001;77: 573-7.
 42. Yao SS, Qureshi E, Syed A, Chaudhry FA. Novel stress echocardiographic model incorporating the extent and severity of wall motion abnormality for risk stratification and prognosis. *Am J Cardiol* 2004;94:715-9.
 43. Travin MI, Heller GV, Johnson LL, et al. The prognostic value of ECG-gated SPECT imaging in patients undergoing stress Tc-99m sestamibi myocardial perfusion imaging. *J Nucl Cardiol* 2004;11: 253-62.
 44. Lima RS, De Lorenzo A, Pantoja MR, Siqueira A. Incremental prognostic value of myocardial perfusion 99m-technetium-sestamibi SPECT in the elderly. *Int J Cardiol* 2004;93:137-43.
 45. Leslie WD, Tully SA, Yogendran MS, Ward LM, Nour KA, Metge CJ. Prognostic value of automated quantification of 99mTc-sestamibi myocardial perfusion imaging. *J Nucl Med* 2005;46:204-11.
 46. Elhendy A, Schinkel AF, van Domburg RT, Bax JJ, Valkema R, Poldermans D. Prediction of all-cause mortality in women with known or suspected coronary artery disease by stress technetium-99m tetrofosmin myocardial perfusion imaging. *Am J Cardiol* 2004;93: 450-2.
 47. Thomas GS, Miyamoto MI, Morello AP 3rd, et al. Technetium 99m sestamibi myocardial perfusion imaging predicts clinical outcome in the community outpatient setting: the Nuclear Utility in the Community (NUC) study. *J Am Coll Cardiol* 2004;43:213-23.
 48. Groutars RG, Verzijlbergen JF, Zwinderman AH, et al. Incremental prognostic value of myocardial SPET with dual-isotope rest (201)Tl/ stress (99m)Tc-tetrofosmin. *Eur J Nucl Med Mol Imaging* 2002;29: 46-52.
 49. Elhendy A, Schinkel AF, van Domburg RT, et al. Risk stratification of patients with angina pectoris by stress 99mTc-tetrofosmin myocardial perfusion imaging. *J Nucl Med* 2005;46:2003-8.
 50. Syed MA, Al-Malki Q, Kazmouz G, et al. Usefulness of exercise echocardiography in predicting cardiac events in an outpatient population. *Am J Cardiol* 1998;82:569-73.
 51. Miller TD, Christian TF, Clements IP, Hodge DO, Gray DT, Gibbons RJ. Prognostic value of exercise thallium-201 imaging in a community population. *Am Heart J* 1998;135:663-70.
 52. Steinberg EH, Koss JH, Lee M, Grunwald AM, Bodenheimer MM. Prognostic significance from 10-year follow-up of a qualitatively normal planar exercise thallium test in suspected coronary artery disease. *Am J Cardiol* 1993;71:1270-3.
 53. Hachamovitch R, Berman DS, Kiat H, et al. Effective risk stratification using exercise myocardial perfusion SPECT in women: gender-related differences in prognostic nuclear testing. *J Am Coll Cardiol* 1996;28:34-44.
 54. Heupler S, Mehta R, Lobo A, Leung D, Marwick TH. Prognostic implications of exercise echocardiography in women with known or suspected coronary artery disease. *J Am Coll Cardiol* 1997;30:414-20.

55. Shaw LJ, Miller DD, Romeis JC, et al. Prognostic value of noninvasive risk stratification in younger and older patients referred for evaluation of suspected coronary artery disease. *J Am Geriatr Soc* 1996;44:1190-7.
56. Marie PY, Danchin N, Durand JF, et al. Long-term prediction of major ischemic events by exercise thallium-201 single-photon emission computed tomography. Incremental prognostic value compared with clinical, exercise testing, catheterization and radionuclide angiographic data. *J Am Coll Cardiol* 1995;26:879-86.
57. Marwick TH, Case C, Vasey C, Allen S, Short L, Thomas JD. Prediction of mortality by exercise echocardiography: a strategy for combination with the duke treadmill score. *Circulation* 2001;103:2566-71.
58. Marwick TH, Mehta R, Arheart K, Lauer MS. Use of exercise echocardiography for prognostic evaluation of patients with known or suspected coronary artery disease. *J Am Coll Cardiol* 1997;30:83-90.
59. Marwick TH, Shaw LJ, Lauer MS, et al. The noninvasive prediction of cardiac mortality in men and women with known or suspected coronary artery disease. Economics of Noninvasive Diagnosis (END) Study Group. *Am J Med* 1999;106:172-8.
60. Shaw LJ, Hachamovitch R, Heller GV, et al. Noninvasive strategies for the estimation of cardiac risk in stable chest pain patients. The Economics of Noninvasive Diagnosis (END) Study Group. *Am J Cardiol* 2000;86:1-7.
61. Diaz LA, Brunken RC, Blackstone EH, Snader CE, Lauer MS. Independent contribution of myocardial perfusion defects to exercise capacity and heart rate recovery for prediction of all-cause mortality in patients with known or suspected coronary heart disease. *J Am Coll Cardiol* 2001;37:1558-64.
62. Cohen Y, Acio E, Heo J, Hughes E, Narula J, Iskandrian AE. Comparison of the prognostic value of qualitative versus quantitative stress tomographic perfusion imaging. *Am J Cardiol* 1999;83:945-8.
63. Snader CE, Marwick TH, Pashkow FJ, Harvey SA, Thomas JD, Lauer MS. Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomography: report of 3,400 patients from a single center. *J Am Coll Cardiol* 1997;30:641-8.
64. Marwick TH, Case C, Short L, Thomas JD. Prediction of mortality in patients without angina: use of an exercise score and exercise echocardiography. *Eur Heart J* 2003;24:1223-30.
65. Yao SS, Qureshi E, Sherrid MV, Chaudhry FA. Practical applications in stress echocardiography: risk stratification and prognosis in patients with known or suspected ischemic heart disease. *J Am Coll Cardiol* 2003;42:1084-90.
66. Kwok JM, Christian TF, Miller TD, Hodge DO, Gibbons RJ. Incremental prognostic value of exercise single-photon emission computed tomographic (SPECT) thallium 201 imaging in patients with ST-T abnormalities on their resting electrocardiograms. *Am Heart J* 2005;149:145-51.
67. Petix NR, Sestini S, Coppola A, et al. Prognostic value of combined perfusion and function by stress technetium-99m sestamibi gated SPECT myocardial perfusion imaging in patients with suspected or known coronary artery disease. *Am J Cardiol* 2005;95:1351-7.
68. Petix NR, Sestini S, Marcucci G, et al. Can the reversible regional wall motion abnormalities on stress gated Tc-99m sestamibi SPECT predict a future cardiac event? *J Nucl Cardiol* 2005;12:20-31.
69. Lombardi F, Tundo F, Terranova P, et al. Prognostic value of C-reactive protein in patients with stress induced myocardial ischemia. *Int J Cardiol* 2005;98:313-7.
70. Liao L, Smith WT 4th, Tuttle RH, Shaw LK, Coleman RE, Borges-Neto S. Prediction of death and nonfatal myocardial infarction in high-risk patients: a comparison between the Duke treadmill score, peak exercise radionuclide angiography, and SPECT perfusion imaging. *J Nucl Med* 2005;46:5-11.
71. Shaw LJ, Hendel RC, Cerquiera M, et al. Ethnic differences in the prognostic value of stress technetium-99m tetrofosmin gated single-photon emission computed tomography myocardial perfusion imaging. *J Am Coll Cardiol* 2005;45:1494-504.
72. Elhendy A, Schinkel AF, Van Domburg RT, Bax JJ, Poldermans D. Prediction of cardiac death in hypertensive patients with suspected or known coronary artery disease by stress technetium-99m tetrofosmin myocardial perfusion imaging. *J Hypertens* 2003;21:1945-51.
73. Borges-Neto S, Tuttle RH, Shaw LK, et al. Outcome prediction in patients at high risk for coronary artery disease: comparison between 99mTc tetrofosmin and 99mTc sestamibi. *Radiology* 2004;232:58-65.
74. Krivokapich J, Child JS, Gerber RS, Lem V, Moser D. Prognostic usefulness of positive or negative exercise stress echocardiography for predicting coronary events in ensuing twelve months. *Am J Cardiol* 1993;71:646-51.
75. Shaw LJ, Hendel R, Borges-Neto S, et al. Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. *J Nucl Med* 2003;44:134-9.
76. Colon PJ 3rd, Mobarek SK, Milani RV, et al. Prognostic value of stress echocardiography in the evaluation of atypical chest pain patients without known coronary artery disease. *Am J Cardiol* 1998;81:545-51.
77. Gaddi O, Tortorella G, Picano E, et al. Diagnostic and prognostic value of vasodilator stress echocardiography in asymptomatic type 2 diabetic patients with positive exercise thallium scintigraphy: a pilot study. *Diabet Med* 1999;16:762-6.
78. Blumenthal RS, Becker DM, Moy TF, Coresh J, Wilder LB, Becker LC. Exercise thallium tomography predicts future clinically manifest coronary heart disease in a high-risk asymptomatic population. *Circulation* 1996;93:915-23.
79. Fagan LF Jr., Shaw L, Kong BA, Caralis DG, Wiens RD, Chaitman BR. Prognostic value of exercise thallium scintigraphy in patients with good exercise tolerance and a normal or abnormal exercise electrocardiogram and suspected or confirmed coronary artery disease. *Am J Cardiol* 1992;69:607-11.
80. Kaul S, Finkelstein DM, Homma S, Leavitt M, Okada RD, Boucher CA. Superiority of quantitative exercise thallium-201 variables in determining long-term prognosis in ambulatory patients with chest pain: a comparison with cardiac catheterization. *J Am Coll Cardiol* 1988;12:25-34.
81. Kang X, Berman DS, Lewin HC, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. *Am Heart J* 1999;138:1025-32.
82. Vanzetto G, Halimi S, Hammoud T, et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. *Diabetes Care* 1999;22:19-26.
83. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. *Am J Cardiol* 2002;90:827-32.
84. Colon PJ 3rd, Guarisco JS, Murgo J, Cheirif J. Utility of stress echocardiography in the triage of patients with atypical chest pain from the emergency department. *Am J Cardiol* 1998;82:1282-4.
85. Borges-Neto S, Shaw LK, Tuttle RH, et al. Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease. *Am J Cardiol* 2005;95:182-8.
86. Marie PY, Mercennier C, Danchin N, et al. Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with beta-blockers. *J Nucl Cardiol* 2003;10:361-8.
87. Zhang X, Liu X, He ZX, et al. Long-term prognostic value of exercise 99mTc-MIBI SPECT myocardial perfusion imaging in patients after percutaneous coronary intervention. *Eur J Nucl Med Mol Imaging* 2004;31:655-62.
88. L'Huillier I, Cottin Y, Touzery C, et al. Predictive value of myocardial tomoscintigraphy in asymptomatic diabetic patients after percutaneous coronary intervention. *Int J Cardiol* 2003;90:165-73.
89. Elhendy A, Schinkel AF, van Domburg RT, Bax JJ, Valkema R, Poldermans D. Prognostic value of stress Tc-99m tetrofosmin SPECT in patients with previous myocardial infarction: impact of scintigraphic extent of coronary artery disease. *J Nucl Cardiol* 2004;11:704-9.
90. Elhendy A, Schinkel AF, van Domburg RT, Bax JJ, Poldermans D. Differential prognostic significance of peri-infarction versus remote myocardial ischemia on stress technetium-99m sestamibi tomography in patients with healed myocardial infarction. *Am J Cardiol* 2004;94:289-93.

91. Elhendy A, Schinkel AF, van Domburg RT, Bax JJ, Valkema R, Poldermans D. Risk stratification of patients after myocardial revascularization by stress Tc-99m tetrofosmin myocardial perfusion tomography. *J Nucl Cardiol* 2003;10:615-22.
92. Fesmire FM, Hughes AD, Stout PK, Wojcik JF, Wharton DR. Selective dual nuclear scanning in low-risk patients with chest pain to reliably identify and exclude acute coronary syndromes. *Ann Emerg Med* 2001;38:207-15.
93. Gentile R, Vitarelli A, Schillaci O, et al. Diagnostic accuracy and prognostic implications of stress testing for coronary artery disease in the elderly. *Ital Heart J* 2001;2:539-45.
94. Launbjerg J, Fruergaard P, Jacobsen HL, Utne HE, Reiber J, Madsen JK. The long-term predictive value of an exercise thallium-201 scintigraphy for patients with acute chest pain but without myocardial infarction. *Coron Artery Dis* 1993;4:195-200.
95. Ben-Gal T, Zafir N. The utility and potential cost-effectiveness of stress myocardial perfusion thallium SPECT imaging in hospitalized patients with chest pain and normal or non-diagnostic electrocardiogram. *Isr Med Assoc J* 2001;3:725-30.
96. Buchsbaum M, Marshall E, Levine B, et al. Emergency department evaluation of chest pain using exercise stress echocardiography. *Acad Emerg Med* 2001;8:196-9.
97. Arruda AM, Das MK, Roger VL, Klarich KW, Mahoney DW, Pellikka PA. Prognostic value of exercise echocardiography in 2,632 patients ≥ 65 years of age. *J Am Coll Cardiol* 2001;37:1036-41.
98. Kwok JM, Christian TF, Miller TD, Hodge DO, Gibbons RJ. Identification of severe coronary artery disease in patients with a single abnormal coronary territory on exercise thallium-201 imaging: the importance of clinical and exercise variables. *J Am Coll Cardiol* 2000;35:335-44.
99. Pavin D, Delonca J, Siegenthaler M, Doat M, Rutishauser W, Righetti A. Long-term (10 years) prognostic value of a normal thallium-201 myocardial exercise scintigraphy in patients with coronary artery disease documented by angiography. *Eur Heart J* 1997;18:69-77.
100. Parisi AF, Hartigan PM, Folland ED. Evaluation of exercise thallium scintigraphy versus exercise electrocardiography in predicting survival outcomes and morbid cardiac events in patients with single- and double-vessel disease. Findings from the Angioplasty Compared to Medicine (ACME) study. *J Am Coll Cardiol* 1997;30:1256-63.
101. Hender AL, Greyson ND, Robinson MG, Freeman MR. Patients with symptomatic ischemia have larger thallium perfusion abnormalities and more adverse prognosis than patients with silent ischemia. *Can J Cardiol* 1992;8:814-8.
102. Brown KA, Rowen M, Altland E. Prognosis of patients with an isolated fixed thallium-201 defect and no prior myocardial infarction. *Am J Cardiol* 1993;72:1199-201.
103. Amanullah AM, Heo J, Iskandrian AE. Impact of exercise single-photon emission computed tomographic imaging on appropriateness of coronary revascularization. *Am J Cardiol* 1998;81:1489-91.
104. Travin MI, Boucher CA, Newell JB, LaRaia PJ, Flores AR, Eagle KA. Variables associated with a poor prognosis in patients with an ischemic thallium-201 exercise test. *Am Heart J* 1993;125:335-44.
105. Moriel M, Rozanski A, Klein J, Berman DS, Merz CN. The limited efficacy of exercise radionuclide ventriculography in assessing prognosis of women with coronary artery disease. *Am J Cardiol* 1995;76:1030-5.
106. Hayashi K, Ohsuzu F, Kosuda S, Nakamura H. Prediction of 6-year prognosis for cardiac event by thallium-201 single-photon emission computed tomography (SPECT) with treadmill exercise test (in Japanese). *Kaku Igaku* 1997;34:443-51.
107. Abdel Fattah A, Kamal AM, Pancholy S, et al. Prognostic implications of normal exercise tomographic thallium images in patients with angiographic evidence of significant coronary artery disease. *Am J Cardiol* 1994;74:769-71.
108. Kipper MS, Labarbera JJ, Krohn LD. The 24-hour Tl-201 image in dual isotope myocardial perfusion scintigraphy: clinical utility and prognostic significance. *Clin Nucl Med* 1998;23:576-81.
109. Candell-Riera J, Santana-Boado C, Bermejo B, et al. Prognosis of "clandestine" myocardial ischemia, silent myocardial ischemia, and angina pectoris in medically treated patients. *Am J Cardiol* 1998;82:1333-8.
110. Krishnan R, Lu J, Dae MW, Botvinick EH. Does myocardial perfusion scintigraphy demonstrate clinical usefulness in patients with markedly positive exercise tests? An assessment of the method in a high-risk subset. *Am Heart J* 1994;127:804-16.
111. Santana-Boado C, Figueras J, Candell-Riera J, et al. Prognosis of patients with angina pectoris or silent ischemia: exercise 99mTc-MIBI SPECT (in Spanish). *Rev Esp Cardiol* 1998;51:297-301.
112. Elhendy A, Schinkel AF, van Domburg RT, Bax JJ, Poldermans D. Prognostic significance of fixed perfusion abnormalities on stress technetium-99m sestamibi single-photon emission computed tomography in patients without known coronary artery disease. *Am J Cardiol* 2003;92:1165-70.
113. Macheourt J, Longere P, Mansour P, et al. Evaluation of prognosis and myocardial ischemia using thallium in myocardial tomoscintigraphy (in French). *Arch Mal Coeur Vaiss* 1993;86:51-5.
114. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Stress myocardial perfusion single-photon emission computed tomography is clinically effective and cost effective in risk stratification of patients with a high likelihood of coronary artery disease (CAD) but no known CAD. *J Am Coll Cardiol* 2004;43:200-8.
115. Elhendy A, Mahoney DW, Khandheria BK, Paterick TE, Burger KN, Pellikka PA. Prognostic significance of the location of wall motion abnormalities during exercise echocardiography. *J Am Coll Cardiol* 2002;40:1623-9.
116. Elhendy A, Shub C, McCully RB, Mahoney DW, Burger KN, Pellikka PA. Exercise echocardiography for the prognostic stratification of patients with low pretest probability of coronary artery disease. *Am J Med* 2001;111:18-23.
117. Elhendy A. Prognostic stratification of diabetic patients by exercise echocardiography. *J Am Coll Cardiol* 2001;37:1551-7.
118. Elhendy A, Modesto KM, Mahoney DW, Khandheria BK, Seward JB, Pellikka PA. Prediction of mortality in patients with left ventricular hypertrophy by clinical, exercise stress, and echocardiographic data. *J Am Coll Cardiol* 2003;41:129-35.
119. McCully RB, Roger VL, Mahoney DW, et al. Outcome after normal exercise echocardiography and predictors of subsequent cardiac events: follow-up of 1,325 patients. *J Am Coll Cardiol* 1998;31:144-9.
120. Chatziioannou SN, Moore WH, Dhekne RD, Ford PV. Women with high exercise tolerance and the role of myocardial perfusion imaging. *Clin Cardiol* 2001;24:475-80.
121. Kaminek M, Myslivecek M, Skvarilova M, et al. Increased prognostic value of combined myocardial perfusion SPECT imaging and the quantification of lung Tl-201 uptake. *Clin Nucl Med* 2002;27:255-60.
122. Berman DS, Hachamovitch R, Kiat H, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. *J Am Coll Cardiol* 1995;26:639-47.
123. Berman DS, Kang X, Van Train KF, et al. Comparative prognostic value of automatic quantitative analysis versus semiquantitative visual analysis of exercise myocardial perfusion single-photon emission computed tomography. *J Am Coll Cardiol* 1998;32:1987-95.
124. Iskandrian AS, Johnson J, Le TT, Wasserleben V, Cave V, Heo J. Comparison of the treadmill exercise score and single-photon emission computed tomographic thallium imaging in risk assessment. *J Nucl Cardiol* 1994;1:144-9.
125. Nozawa M, Tamaki N, Sugihara H, et al. Value of stress-rest ECG gated SPECT one day protocol using 99mTc-MIBI (in Japanese). *Kaku Igaku* 1995;32:1363-8.
126. Gibbons RJ, Hodge DO, Berman DS, et al. Long-term outcome of patients with intermediate-risk exercise electrocardiograms who do not have myocardial perfusion defects on radionuclide imaging. *Circulation* 1999;100:2140-5.
127. Nallamouthu N, Araujo L, Russell J, Heo J, Iskandrian AE. Prognostic value of simultaneous perfusion and function assessment using technetium-99m sestamibi. *Am J Cardiol* 1996;78:562-4.
128. Pancholy SB, Fattah AA, Kamal AM, Ghods M, Heo J, Iskandrian AS. Independent and incremental prognostic value of exercise thallium single-photon emission computed tomographic imaging in women. *J Nucl Cardiol* 1995;2:110-6.
129. Schalet BD, Kegel JG, Heo J, Segal BL, Iskandrian AS. Prognostic implications of normal exercise SPECT thallium images in patients with strongly positive exercise electrocardiograms. *Am J Cardiol* 1993;72:1201-3.

130. Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. *Circulation* 1996;93:905-14.
131. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. *Circulation* 1998;97:535-43.
132. Hachamovitch R, Berman DS, Kiat H, Cohen I, Friedman JD, Shaw LJ. Value of stress myocardial perfusion single photon emission computed tomography in patients with normal resting electrocardiograms: an evaluation of incremental prognostic value and cost-effectiveness. *Circulation* 2002;105:823-9.
133. Brown KA, Rowen M. Impact of antianginal medications, peak heart rate and stress level on the prognostic value of a normal exercise myocardial perfusion imaging study. *J Nucl Med* 1993;34:1467-71.
134. Brown KA, Rowen M. Prognostic value of a normal exercise myocardial perfusion imaging study in patients with angiographically significant coronary artery disease. *Am J Cardiol* 1993;71:865-7.
135. Brown KA, Altland E, Rowen M. Prognostic value of normal technetium-99m-sestamibi cardiac imaging. *J Nucl Med* 1994;35:554-7.
136. Hilton TC, Shaw LJ, Chaitman BR, Stocke KS, Goodgold HM, Miller DD. Prognostic significance of exercise thallium-201 testing in patients aged greater than or equal to 70 years with known or suspected coronary artery disease. *Am J Cardiol* 1992;69:45-50.
137. Oosterhuis WP, Breeman A, Niemeyer MG, et al. Patients with a normal exercise thallium-201 myocardial scintigram: always a good prognosis? *Eur J Nucl Med* 1993;20:151-8.
138. Zanco P, Zampiero A, Favero A, et al. Myocardial technetium-99m sestamibi single-photon emission tomography as a prognostic tool in coronary artery disease: multivariate analysis in a long-term prospective study. *Eur J Nucl Med* 1995;22:1023-8.
139. Hoque A, Maaieh M, Longaker RA, Stoddard MF. Exercise echocardiography and thallium-201 single-photon emission computed tomography stress test for 5- and 10-year prognosis of mortality and specific cardiac events. *J Am Soc Echocardiogr* 2002;15:1326-34.
140. Arruda-Olson AM, Juracan EM, Mahoney DW, McCully RB, Roger VL, Pellika PA. Prognostic value of exercise echocardiography in 5,798 patients: is there a gender difference? *J Am Coll Cardiol* 2002;39:625-31.
141. Boyne TS, Koplak BA, Parsons WJ, Smith WH, Watson DD, Beller GA. Predicting adverse outcome with exercise SPECT technetium-99m sestamibi imaging in patients with suspected or known coronary artery disease. *Am J Cardiol* 1997;79:270-4.
142. Chatziioannou SN, Moore WH, Ford PV, et al. Prognostic value of myocardial perfusion imaging in patients with high exercise tolerance. *Circulation* 1999;99:867-72.
143. del Val Gomez M, Gallardo FG, Salazar ML, Terol I. Prognostic value of normal myocardial radionuclide scan in patients with positive treadmill test (in Spanish). *Rev Esp Cardiol* 2002;55:991-4.
144. Galassi AR, Azzarelli S, Tomaselli A, et al. Incremental prognostic value of technetium-99m-tetrofosmin exercise myocardial perfusion imaging for predicting outcomes in patients with suspected or known coronary artery disease. *Am J Cardiol* 2001;88:101-6.
145. Kaminek M, Myslivecek M, Skvarilova M, et al. Prognostic significance of stress tomographic scintigraphy of myocardial perfusion in diabetic patients (in Czech). *Vnitr Lek* 2001;47:739-43.
146. Zerahn B, Jensen BV, Nielsen KD, Moller S. Increased prognostic value of combined myocardial perfusion imaging and exercise electrocardiography in patients with coronary artery disease. *J Nucl Cardiol* 2000;7:616-22.
147. Vanzetto G, Ormezzano O, Fagret D, Comet M, Denis B, Mache-court J. Long-term additive prognostic value of thallium-201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: study in 1137 patients with 6-year follow-up. *Circulation* 1999;100:1521-7.
148. Sugihara H, Tamaki N, Mitsunami K, Kinoshita M. Prognostic value of 1-day stress/rest electrocardiogram-gated single-photon emission computed tomography using Tc-99m-labeled methoxy-isobutyl isonitrite. *Jpn Circ J* 1998;62:405-8.
149. Stratmann HG, Williams GA, Wittry MD, Chaitman BR, Miller DD. Exercise technetium-99m sestamibi tomography for cardiac risk stratification of patients with stable chest pain. *Circulation* 1994;89:615-22.
150. Soman P, Parsons A, Lahiri N, Lahiri A. The prognostic value of a normal Tc-99m sestamibi SPECT study in suspected coronary artery disease. *J Nucl Cardiol* 1999;6:252-6.
151. Schinkel AF, Elhendy A, van Domburg RT, et al. Incremental value of exercise technetium-99m tetrofosmin myocardial perfusion single-photon emission computed tomography for the prediction of cardiac events. *Am J Cardiol* 2003;91:408-11.
152. Raiker K, Sinusas AJ, Wackers FJ, Zaret BL. One-year prognosis of patients with normal planar or single-photon emission computed tomographic technetium 99m-labeled sestamibi exercise imaging. *J Nucl Cardiol* 1994;1:449-56.
153. Pattillo RW, Fuchs S, Johnson J, et al. Predictors of prognosis by quantitative assessment of coronary angiography, single photon emission computed tomography thallium imaging, and treadmill exercise testing. *Am Heart J* 1996;131:582-90.
154. Olmos LI, Dakik H, Gordon R, et al. Long-term prognostic value of exercise echocardiography compared with exercise 201Tl, ECG, and clinical variables in patients evaluated for coronary artery disease. *Circulation* 1998;98:2679-86.
155. Hachamovitch R, Hayes S, Friedman JD, et al. Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: what is the warranty period of a normal scan? *J Am Coll Cardiol* 2003;41:1329-40.
156. Elhendy A, Schinkel A, Bax JJ, van Domburg RT, Poldermans D. Long-term prognosis after a normal exercise stress Tc-99m sestamibi SPECT study. *J Nucl Cardiol* 2003;10:261-6.
157. Ambrosi P, Bruneau P, Faugere G, et al. Prognostic value of thallium-201 myocardial scintigraphy in patients with hypertension, suspected of coronary disease (in French). *Ann Cardiol Angeiol (Paris)* 1993;42:479-83.
158. Sawada SG, Ryan T, Conley MJ, Corya BC, Feigenbaum H, Armstrong WF. Prognostic value of a normal exercise echocardiogram. *Am Heart J* 1990;120:49-55.
159. Ismail G, Lo E, Sada M, Conant RD, Shapiro SM, Ginzton LE. Long-term prognosis of patients with a normal exercise echocardiogram and clinical suspicion of myocardial ischemia. *Am J Cardiol* 1995;75:934-6.
160. Hachamovitch R, Shaw L, Berman DS. Methodological considerations in the assessment of noninvasive testing using outcomes research: pitfalls and limitations. *Prog Cardiovasc Dis* 2000;43:215-30.
161. Grady D, Chaput L, Kristof M. Diagnosis and Treatment of Coronary Heart Disease in Women: Systematic Reviews of Evidence on Selected Topics. Evidence Report/Technology Assessment No. 81. (Prepared by the University of California, San Francisco-Stanford Evidence-based Practice Center under Contract No 290-97-0013.) AHRQ Publication No. 03-E037. Rockville, MD: Agency for Healthcare Research and Quality, 2003.
162. American Heart Association. Heart Disease and Stroke Statistics—2004 Update. Dallas, TX: American Heart Association, 2003.
163. Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. *Ann Intern Med* 2002;137:598-602.
164. Aktas MK, Ozduran V, Pothier CE, Lang R, Lauer MS. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. *JAMA* 2004;292:1462-8.
165. Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. *JAMA* 2003;290:1600-7.
166. Lauer MS. Is heart rate recovery a modifiable risk factor? *J Cardiopulm Rehabil* 2003;23:88-9.
167. Cheng YJ, Lauer MS, Earnest CP, et al. Heart rate recovery following maximal exercise testing as a predictor of cardiovascular disease and all-cause mortality in men with diabetes. *Diabetes Care* 2003;26:2052-7.
168. Abidov A, Bax JJ, Hayes SW, et al. Transient ischemic dilation ratio of the left ventricle is a significant predictor of future cardiac events in patients with otherwise normal myocardial perfusion SPECT. *J Am Coll Cardiol* 2003;42:1818-25.
169. Matsuo S, Matsumoto T, Nakae I, et al. Prognostic value of ECG-gated thallium-201 single-photon emission tomography in patients with coronary artery disease. *Ann Nucl Med* 2004;18:617-22.